Reverse TCM: The World's First Innovative TCM Drug Achieving Long-Term Diabetes Remission

Our innovative Traditional Chinese Medicine therapy with glucose-lowering efficacy comparable to semaglutide — and the world's first time-limited-dosing diabetes therapy achieving long-term remission in a high proportion of patients.

Explore the Science
Key Highlights

Marked Clinical Efficacy Addressing a Hard Clinical Need

World's First

First innovative TCM drug used alone for glycemic control, with efficacy comparable to semaglutide.

Time-Limited Dosing

Therapy withdrawn after just 3–5 months, with benefits extending to lipids, uric acid, and more.

Long-Term Remission

High proportion of patients remain in remission; longest follow-up 36 months. Most achieve treatment de-escalation.

1,000+ Patients

2019–2024: over 1,000 patients treated with marked clinical efficacy across multiple institutions.

Development Milestones

Strong Developability & Regulatory Progress

1

2019–2024

Over 1,000 patients treated across real-world settings with marked clinical efficacy.

2

2024–2025

GCP multicenter, randomized, double-blind IIT in 95 subjects led by Prof. Ji Linong further validated efficacy.

3

April 2026

Phase II clinical trial approval obtained from the NMPA (CDE). Extensive human-use experience substantially de-risks development.

Market Opportunity

The Global Diabetes Drug Market Exceeds RMB 600 Billion

Global Market

The global diabetes drug market reached USD 97.41 billion in 2023 and is projected to reach nearly USD 110 billion by 2030. Overall diabetes prevalence stands at 10% worldwide.

China Market

China's diabetes drug market reached RMB 133.892 billion in 2023, growing year over year, driven by rising affordability, improved insurance coverage, and ongoing development of innovative antidiabetic agents.

Global Prevalence

Diabetes Is Rising Across Every Region

134%

Africa (AFR)

24M → 55M by 2045

87%

MENA

73M → 136M by 2045

68%

South-East Asia

90M → 152M by 2045

50%

S. & C. America

32M → 49M by 2045

The Science

TCM & Western Medicine: Aligned Understanding of Diabetes Pathogenesis

Western Medicine

1. Decline in insulin's capacity to regulate glucose metabolism (insulin resistance)
2. Reduced insulin secretion from islet beta-cell dysfunction

TCM Framework

Branch (标): 'Phlegm-fluid retention' obstructs receptor utilization of blood glucose
Root (本): 'Over-taxation' of the pancreas — spleen-yin insufficiency

Mechanism

Two Formulas, One Goal: Restoring Metabolic Capability

Root Formula (本)

Nourishes yin, fortifies the spleen — restores pancreatic function.

Branch Formula (标)

Resolves phlegm, transforms retained fluid — eliminates insulin resistance.

Spiral Ascent

Zang-fu qi ascends in a rising spiral — enhanced capacity to metabolize glucose and other substrates. 'Yin at peace, yang secured' — health restored.

Treatment Paradigm

From Lifelong Drug Addition to Treatment With an Endpoint

× Existing Pathway: Escalation Only

Lifestyle → Metformin → Dual oral → Triple oral → Insulin initiation → Intensified insulin. Every step adds more drugs. No way back.

✓ Root-and-Branch Sequential Pathway

Day 1: Stop all oral antidiabetic drugs.
Months 1–2: Taper and stop insulin.
Months 3–6: Formulas A and B alternate.
At target: TCM stopped completely.
After withdrawal: Maintained by the body itself.

Real-World Evidence

625 Real-World Cases: Effective Across All Three Patient Populations

From 15 medical institutions (September 2019 – August 2026), 625 patients with baseline HbA1c ≥7.0% received Formula A/B sequentially. Mean HbA1c fell from 8.56% to 6.91%, with a 64% target-attainment rate.

-1.75

Treatment-Naive

163 pts | HbA1c 8.70% → 6.95% | 63.8% at target

-1.62

OAD-Experienced

410 pts | HbA1c 8.50% → 6.88% | 64.1% at target

-1.70

Insulin-Experienced

52 pts | HbA1c 8.63% → 6.93% | 50.0% at target

Case Study 1

Treatment-Naive Patient: Stopped at 2 Months, Still in Remission at 24 Months

Patient Yang

Female, 74 years old
Diabetes: 1 month
No prior antidiabetic drug
Comorbidity: hypertension

HbA1c Journey

First Visit

HbA1c 9.3%

Withdrawal

HbA1c 6.4%

24-Month Follow-up

HbA1c 5.8%

Case Study 2

OAD-Experienced: Inadequate Control on Metformin → Remission After 3 Months

Patient Liu

Male, 40 years old
Diabetes: 4 years
Prior: metformin (inadequate control)
No comorbidities

HbA1c Journey

HbA1c fell from 8.6% → 5.9% at withdrawal after 3 months of sequential therapy. Maintained at 5.9% for 4 months off all treatment. Additional benefit: uric acid 479.3 → 373 μmol/L.

Case Study 3

Triple-Oral Failure: HbA1c at Target in 3 Months, All Drugs Stopped at 5 Months

Patient Wang

Female, 57 years old
Diabetes: 6 years
Prior: metformin + glimepiride + acarbose
Comorbidity: obesity (BMI 28.4)

HbA1c Journey

First Visit

HbA1c 10.4%

3 Months

At target 6.8%

5 Months

All drugs stopped 6.2%

Additional benefit: weight −7.45 kg; fasting glucose 15.36 → 7.46; postprandial 17.29 → 6.19.

Insulin Discontinuation

67.3% of Insulin-Experienced Patients Fully Discontinued Insulin — Far Exceeding GLP-1RA, SGLT-2i & DPP-4i

67.3%

A/B Sequential

35 of 52 insulin-experienced patients fully discontinued insulin. Median time to discontinuation: 24 days.

16.7%

GLP-1RA

Added to basal insulin (n=8,869 matched pairs)

17.9%

SGLT-2i

Added to basal insulin (same matched study)

17.1%

DPP-4i

Added to basal insulin (same matched study)

Case Study 4

Insulin + 4 Oral Agents: Injections Stopped in Under 1 Month, All Drugs Stopped at 6 Months

Patient Zhang

Female, 59 years old
Diabetes: 10 years
Prior: insulin glargine + metformin, glimepiride, acarbose, dapagliflozin
Site: Beijing Xuanwu Hospital of TCM

HbA1c Journey

HbA1c: 10.2% → 6.1% at withdrawal. Insulin fully discontinued within 1 month; all drugs stopped at 6 months. Additional benefit: urinary microalbumin 57 → 9.9 mg/L; C-peptide improved (1.38 → 2.62); weight −5 kg.

Multi-Parameter Benefit

Beyond Glucose: Five Metabolic Indicators Improve in Parallel

Among 431 patients with ≥3 elevated parameters before treatment, 74.2% improved on every elevated parameter. Among 370 with both glucose and lipids elevated, 90.0% improved in both domains.

Metabolic Data

What Is Elevated Comes Down — Independently and Within the Same Patient

Post-Withdrawal Remission

Most Patients Maintain Remission After Stopping All Drugs

52.7%

Still <6.5% at 3 Months

29 of 55 patients who returned for testing at 3 months off treatment remained below 6.5%.

8.15%

Pre-Treatment HbA1c

Same cohort: 8.15% before treatment vs. 6.47% at re-test 3 months after withdrawal — 1.68 pp lower (P<0.001).

58.1%

Still <7.0% at 6 Months

18 of 31 patients who returned at 6 months off treatment remained below 7.0%. Only 4 of 55 returned above 8.0%.

Phase II Design

The Phase II Protocol Writes 'After Withdrawal' Into the Design

Phase II Questions

Two Critical Questions This Trial Must Answer

Q1. Question 1: Remission Rate

How many patients achieve clinical remission at 3 months off treatment? The 12-week core withdrawal follow-up period provides the primary readout.

Q2. Question 2: Durability

At one full year off treatment, is that remission state still maintained? The 52-week long-term follow-up answers this question definitively.

Summary

Reverse TCM: Turning Diabetes Care From Lifelong Drug Addition Into Treatment With an Endpoint

Innovative

World's first Category 1.1 innovative TCM drug for glycemic control, efficacy comparable to semaglutide.

Proven

1,000+ patients treated; mean HbA1c reduction of 1.66 pp across all three patient populations.

Time-Limited

3–5 months of therapy, then stop. No lifelong maintenance. Treatment has a true endpoint.

Regulatory

Phase II approval from NMPA (CDE) obtained April 2026. Extensive human-use experience de-risks development.